4:41 PM
 | 
Aug 03, 2018
 |  BioCentury  |  Emerging Company Profile

Compass’ range

How Compass’ technology generates large multispecific libraries

Compass Therapeutics LLC combines human cell display, high throughput antibody screening and a multispecific engineering platform to develop large libraries of cancer and autoimmune therapies.

Traditional approaches to antibody discovery use hybridoma fusions in animals, phage display or yeast cell surface display, followed by a humanizing step, which co-founder and CEO Thomas Schuetz said generates smaller libraries of antibodies with less epitopic diversity than Compass’ approach.

Compass clones human antibodies discovered via phage display into a human cell display system. The approach “allows almost instantaneous genotype-phenotype linkage, with one antibody gene expressed per human cell displayed on the surface of the human cell,” said Schuetz, adding that high volumes of antibodies can then be screened rapidly via flow cytometry.

“We generate candidate sets that have extremely broad epitopic coverage to the target. And one of...

Read the full 662 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >